Update: Investigation of bioterrorism-related anthrax and interim guidelines for exposure management and antimicrobial therapy, October 2001.
Since October 3, 2001, CDC and state and local public health authorities have been investigating cases of bioterrorism-related anthrax. This report updates previous findings, provides new information on case investigations in two additional areas, presents the susceptibility patterns of Bacillus anthracis isolates, and provides interim recommendations for managing potential threats and exposures and for treating anthrax.
D000328:Adult; D000881:Anthrax / Q000188:drug therapy / Q000453:epidemiology / Q000517:prevention & control; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D019072:Antibiotic Prophylaxis; D001408:Bacillus anthracis / Q000187:drug effects / Q000235:genetics / Q000302:isolation & purification*; D023482:Bioterrorism; D002648:Child; D002939:Ciprofloxacin / Q000627:therapeutic use; D004219:District of Columbia / Q000453:epidemiology; D004318:Doxycycline / Q000627:therapeutic use; D005260:Female; D005431:Florida / Q000453:epidemiology; D006077:Government Agencies; D006801:Humans; D008297:Male; D008396:Maryland / Q000453:epidemiology; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D009515:New Jersey / Q000453:epidemiology; D009518:New York / Q000453:epidemiology; D016273:Occupational Exposure / Q000517:prevention & control; D011177:Postal Service; D015980:Public Health Practice; D012141:Respiratory Tract Infections / Q000188:drug therapy / Q000453:epidemiology / Q000517:prevention & control; D017192:Skin Diseases, Bacterial / Q000188:drug therapy / Q000453:epidemiology / Q000517:prevention & control; D013171:Spores, Bacterial / Q000302:isolation & purification*; D014481:United States / Q000453:epidemiology; D014768:Virginia / Q000453:epidemiology
D000900:Anti-Bacterial Agents; D002939:Ciprofloxacin; D004318:Doxycycline